Journal
VACCINE
Volume 34, Issue 2, Pages 270-275Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2015.11.034
Keywords
Bivalent vaccine; Mycoplasma hyopneumoniae; Porcine circovirus-associated disease; Porcine circovirus type 2; Porcine respiratory disease complex
Categories
Funding
- Research Institute for Veterinary Science (RIVS) from the College of Veterinary Medicine [550-20140098]
- BK 21 Plus Program for Creative Veterinary Science Research [5260-20150100]
Ask authors/readers for more resources
The objective of this study was to evaluate the efficacy of a new bivalent vaccine (Fostera (TM) PCV MH, Zoetis) of porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae in growing pigs under experimental conditions. A total of 80 pigs were randomly divided into 8 groups (10 pigs per group). The pigs were administered the bivalent vaccine intramuscularly as a 2.0 mL dose at 21 days of age based on the manufacturer's instructions. Three weeks after vaccination, the pigs were inoculated with either PCV2 (intranasal route) or M. hyopneumoniae (intratracheal route) or both. Regardless of the type of inoculation, vaccinated pigs after challenge exhibited effective reduction of clinical signs, PCV2 viremia levels and mycoplasma nasal shedding, and lung and lymphoid lesion when compared to unvaccinated challenged pigs. Vaccinated challenged pigs had significantly higher (P< 0.05) levels of PCV2-specific neutralizing antibodies, and numbers of PCV2-and M. hyopneumoniae-specific interferon-gamma secreting cells compared to unvaccinated challenged pigs. This study demonstrates that the bivalent vaccine is able to protect pigs against either PCV2 or M. hyopneumonive infection or both based on clinical, microbiological, immunological, and pathological evaluation. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available